The pipeline and commercial market for novel antimicrobial drugs is insufficient to address current and future patient needs or mitigate the loss of effective treatments as antimicrobial resistance spreads. The U.S. Government implements a range of efforts to ensure sustainable availability of antimicrobial treatments, supporting research, product development, and appropriate use. Opportunities remain to expand appropriate access to antimicrobial drugs domestically and globally and support the sustainable development of antimicrobial drugs into the future, despite the evolution of antimicrobial resistance.
